endometrial cancer Osteoporosis
Conditions
Interventions
Group I: alfacalcidol (1microgram/day) and calcium aspartate 1.2g/day Drug admimistration period is 24 months.
Group II: alfacalcidol (1microgram/day) and Raloxifene (60mg/day) and calcium aspartate
Sponsors
Osaka University Graduate School of Medicine, Department of Obstetrics and Gynecology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: The patients who were diagnosed with endometrial cancer and underwent a surgery including bilateral oophorectomy at the five institutions participating in this study between 2004 and 2011.
Exclusion criteria
Exclusion criteria: Patients who refuse participation in this study. Patients who had taken bisphosphonates, estrogen or progestin within the previous 1 year, or vitamin D3, vitamin K2, or ipiriflavone within previous 3 months. Patients who raloxifene, alfacalcidol, or Calcium L-Aspartate Hydrate is contraindicated for. Patients whose lumber BMD was above +2.5 S.D. at the enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage change of bone mineral density of lumber spine and femoral neck | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profiles | — |
Countries
Japan
Contacts
Public ContactKoji Nakamura
Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology
Outcome results
None listed